2026 Global: Chemotherapy Infusion Pumps Market -Competitive Review (2032) report
Description
The 2026 Global: Chemotherapy Infusion Pumps Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
B. Braun Melsungen AG, headquartered in Melsungen, Germany, is among the most influential players in the chemotherapy infusion pumps market, with its Infusomat line deployed widely in hospital oncology wards to deliver cytotoxic drugs with precise dosing and safety safeguards. Becton, Dickinson and Company (BD), based in Franklin Lakes, New Jersey, United States, commands a large market share through the BD Alaris family of infusion pumps, renowned for programmable flow control, dose error reduction, and scalable configurations for chemotherapy administration. Baxter International Inc., headquartered in Deerfield, Illinois, United States, maintains a substantial presence in intravenous therapy devices, including syringe and volumetric pumps that support cytotoxic regimens across inpatient, ambulatory, and infusion center settings. Terumo Corporation, headquartered in Tokyo, Japan, supplies high-precision infusion solutions that span syringe and volumetric pumps, integrating with oncology workflows and electronic medical records to ensure traceability and safety in drug delivery.
Fresenius Kabi AG, headquartered in Bad Homburg vor der Höhe, Germany, offers comprehensive intravenous infusion systems and drug-delivery platforms that support chemotherapy regimens in hospital and home-care settings, with a focus on safety features and interoperability. ICU Medical, Inc., based in San Clemente, California, United States, emphasizes advanced infusion therapy with automated, programmable pumps that handle high-dose cytotoxic regimens in critical care and oncology units, along with closed-loop safety features and consumable compatibility. Smiths Medical, a division of Smiths Group headquartered in London, United Kingdom, contributes syringe and volumetric infusion pumps such as CADD models that are widely used for chemotherapy administration in hospital settings and specialty clinics, supported by a global service network and regulatory-compliant software. These offerings reflect the convergence of safety, interoperability, and scalable deployment essential to modern oncology infusion programs.
Pfizer Inc., operating Hospira infusion pump platforms within its oncology portfolio, is headquartered in New York City, United States, and maintains a significant role in the manufacture and supply of chemotherapy infusion systems through legacy brands and collaboration-driven lines. Medtronic plc, headquartered in Dublin, Ireland, participates in the broader intravenous infusion pump market through its medical device portfolio, which includes programmable pumps used in oncology care and anesthesia, with a strong emphasis on patient monitoring integration and data connectivity. Nipro Corporation, headquartered in Osaka, Japan, rounds out the roster of key players by delivering syringe and infusion pump devices, along with related consumables, that support chemotherapy administration across diverse healthcare settings and markets. Continued convergence with digital health, remote monitoring, and data analytics will further distinguish these firms in chemotherapy delivery performance and safety globally.
B. Braun Melsungen AG, headquartered in Melsungen, Germany, is among the most influential players in the chemotherapy infusion pumps market, with its Infusomat line deployed widely in hospital oncology wards to deliver cytotoxic drugs with precise dosing and safety safeguards. Becton, Dickinson and Company (BD), based in Franklin Lakes, New Jersey, United States, commands a large market share through the BD Alaris family of infusion pumps, renowned for programmable flow control, dose error reduction, and scalable configurations for chemotherapy administration. Baxter International Inc., headquartered in Deerfield, Illinois, United States, maintains a substantial presence in intravenous therapy devices, including syringe and volumetric pumps that support cytotoxic regimens across inpatient, ambulatory, and infusion center settings. Terumo Corporation, headquartered in Tokyo, Japan, supplies high-precision infusion solutions that span syringe and volumetric pumps, integrating with oncology workflows and electronic medical records to ensure traceability and safety in drug delivery.
Fresenius Kabi AG, headquartered in Bad Homburg vor der Höhe, Germany, offers comprehensive intravenous infusion systems and drug-delivery platforms that support chemotherapy regimens in hospital and home-care settings, with a focus on safety features and interoperability. ICU Medical, Inc., based in San Clemente, California, United States, emphasizes advanced infusion therapy with automated, programmable pumps that handle high-dose cytotoxic regimens in critical care and oncology units, along with closed-loop safety features and consumable compatibility. Smiths Medical, a division of Smiths Group headquartered in London, United Kingdom, contributes syringe and volumetric infusion pumps such as CADD models that are widely used for chemotherapy administration in hospital settings and specialty clinics, supported by a global service network and regulatory-compliant software. These offerings reflect the convergence of safety, interoperability, and scalable deployment essential to modern oncology infusion programs.
Pfizer Inc., operating Hospira infusion pump platforms within its oncology portfolio, is headquartered in New York City, United States, and maintains a significant role in the manufacture and supply of chemotherapy infusion systems through legacy brands and collaboration-driven lines. Medtronic plc, headquartered in Dublin, Ireland, participates in the broader intravenous infusion pump market through its medical device portfolio, which includes programmable pumps used in oncology care and anesthesia, with a strong emphasis on patient monitoring integration and data connectivity. Nipro Corporation, headquartered in Osaka, Japan, rounds out the roster of key players by delivering syringe and infusion pump devices, along with related consumables, that support chemotherapy administration across diverse healthcare settings and markets. Continued convergence with digital health, remote monitoring, and data analytics will further distinguish these firms in chemotherapy delivery performance and safety globally.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
